208 related articles for article (PubMed ID: 25347006)
1. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Bone Marrow Transplant; 2015 Feb; 50(2):204-8. PubMed ID: 25347006
[TBL] [Abstract][Full Text] [Related]
2. Impact of early relapse after auto-SCT for multiple myeloma.
Kumar S; Mahmood ST; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Sep; 42(6):413-20. PubMed ID: 18587435
[TBL] [Abstract][Full Text] [Related]
3. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
4. Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.
Yhim HY; Kim K; Kim JS; Kang HJ; Kim JA; Min CK; Bae SH; Park E; Yang DH; Suh C; Kim MK; Mun YC; Eom HS; Shin HJ; Yoon HJ; Kwon JH; Lee JH; Kim YS; Yoon SS; Kwak JY
Bone Marrow Transplant; 2013 Mar; 48(3):425-32. PubMed ID: 22941384
[TBL] [Abstract][Full Text] [Related]
5. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
Olin RL; Vogl DT; Porter DL; Luger SM; Schuster SJ; Tsai DE; Siegel DL; Cook RJ; Mangan PA; Cunningham K; Stadtmauer EA
Bone Marrow Transplant; 2009 Mar; 43(5):417-22. PubMed ID: 18850013
[TBL] [Abstract][Full Text] [Related]
6. Second auto-SCT for treatment of relapsed multiple myeloma.
Gonsalves WI; Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Dingli D; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2013 Apr; 48(4):568-73. PubMed ID: 23000647
[TBL] [Abstract][Full Text] [Related]
7. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after auto-SCT in African Americans with multiple myeloma.
Khaled Y; Abidi MH; Janakiraman N; Kato K; Levine JE; Reddy P; Medina M; Peres E; Hanbali A; Mineishi S
Bone Marrow Transplant; 2009 Jun; 43(11):845-51. PubMed ID: 19139731
[TBL] [Abstract][Full Text] [Related]
9. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
10. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
[TBL] [Abstract][Full Text] [Related]
13. Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
Leng S; Moshier E; Tremblay D; Hu L; Biran N; Barman N; Parekh S; Cho H; Madduri D; Richter J; Barlogie B; Jagannath S; Chari A
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e734-e751. PubMed ID: 32660906
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
16. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N;
Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704
[TBL] [Abstract][Full Text] [Related]
17. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
[TBL] [Abstract][Full Text] [Related]
18. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
19. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation.
Yi ES; Son MH; Hyun JK; Cho HW; Ju HY; Lee JW; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2020 Feb; 67(2):e28066. PubMed ID: 31736249
[TBL] [Abstract][Full Text] [Related]
20. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.
Richter S; Böttcher M; Stoll A; Zeremski V; Völkl S; Mackensen A; Ekici AB; Jacobs B; Mougiakakos D
Transplant Cell Ther; 2024 Jun; 30(6):628.e1-628.e9. PubMed ID: 38460727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
